Trial · NCT03011021
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
NCT03011021, Phase 1, Phase 2, Unknown, Second Xiangya Hospital of Central South University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes. Trials, record NCT03011021. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03011021
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
- NCT number
- NCT03011021
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Conditions
- Type1 Diabetes Mellitus, Autoimmune Diabetes
- Interventions
- Liraglutide, UCB-Treg, Insulin
- First posted
- 2017-01-05
- Last updated
- 2023-03-14
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse effects | 2 years | Primary outcome measures will be the number of participants with adverse events, laboratory abnormalities and other signs of toxicity. Particular focus will be on the number and severity of infusion reactions, complications related to infection, and any potential negative impact on the course of diabetes. |
| Secondary | Change in HbA1C | 2 years | Measure the HbA1C level after treatment |
| Secondary | Change in C-peptide | 2 years | Measure the C-peptide level after treatment |
| Secondary | Change in insulin dose | 2 years | Measure insulin dose patient used after treatment |
| Secondary | Hypoglycaemic events | 2 years | Measure the number of participants with Hypoglycaemic events |
| Secondary | Change in titer of autoantibodies | 2 years | Measure the titer of antoantibodies of participant after treatment |
| Secondary | Change in immune cells diversities and quantities. | 2 years | Measure the immune cells diversities and quantities after treatment |
| Secondary | Change in autoimmune-related cytokines | 2 years | Measure the change of autoimmune- related cytokines after treatment |
| Secondary | Life quality evaluation | 2 years | Number of participants with disturbance of emotion, sleep, resting or energy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03011021
GET https://conductscience.org/api/trials/v1/NCT03011021/registered